# A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma

> **NCT03697629** · PHASE2 · COMPLETED · sponsor: **Canadian Myeloma Research Group** · enrollment: 40 (actual)

## Conditions studied

- Multiple Myeloma in Relapse

## Interventions

- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT03697629
- **Lead sponsor:** Canadian Myeloma Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-03
- **Primary completion:** 2020-07-21
- **Final completion:** 2021-12-20
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2022-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03697629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03697629, "A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03697629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*